
    
      200 patients are prospectively randomized in a double blind study investigating the efficacy
      of levosimendan in heart failure after cardiac surgery. Levosimendan/placebo is administered
      as 24 hour continuous infusion beginning after anesthesia induction. Primary endpoint being
      adrenergic inotrope need after cardiopulmonary bypass and secondary endpoints hospital and
      6-month mortality and major organ failure.
    
  